Iodoacetamide blank compensation in FXIII functional assays: Is it still necessary?
Int J Lab Hematol
.
2023 Dec;45(6):969-971.
doi: 10.1111/ijlh.14111.
Epub 2023 Jun 8.
Authors
Philippe Savard
1
,
Vanessa Leguy-Seguin
2
,
Camille Chavy
3
,
Fabienne Genre-Volot
4
,
Anamaria Callegarin
4
,
Jean Amiral
5
,
Bernard Bonnotte
2
6
,
Thomas Lecompte
1
7
,
Emmanuel de Maistre
1
Affiliations
1
Laboratory Haematology, University Hospital Centre of Dijon Bourgogne, Dijon, France.
2
Division of Internal Medicine, Competence Centre for Autoimmune Cytopenia, University Hospital Centre of Dijon, Dijon, France.
3
Division of Paediatrics, University Hospital Centre of Dijon, Dijon, France.
4
Resources and Competence Centre for Constitutional Bleeding Disorders, University Hospital Centre of Dijon, Dijon, France.
5
Hyphen Biomed, Neuville-sur-Oise, France.
6
INSERM UMR1098, University of Bourgogne Franche-Comté, EFS Bourgogne Franche-Comté, Besançon, France.
7
Faculty of medicine, University of Lorraine, Nancy, France.
PMID:
37293692
DOI:
10.1111/ijlh.14111
No abstract available
Publication types
Letter
MeSH terms
Factor XIII Deficiency*
Factor XIII*
Humans
Iodoacetamide
Substances
Iodoacetamide
Factor XIII